Lakewood-Amedex Biotherapeutics announced that their Bisphosphocin® compound Nu-8 achieved up to 97% inhibition of E. coli growth in rodents with urinary tract infections. The Bisphosphocin® class also demonstrated broad activity against resistant bacteria in both urinary and pulmonary infection models, including drug-resistant strains and biofilm-forming organisms. These results highlight the potential of Bisphosphocin® compounds as fast-acting, broad-spectrum antimicrobials to address antibiotic resistance. The company is advancing its lead candidate Nu-3 in a Phase 2a trial for diabetic foot ulcers, with data expected in early 2027.
Lakewood-Amedex Biotherapeutics' Bisphosphocin® compounds are highlighted here with Pluang's Health-sector market data as of Oct 07, 2026 19:12 WIB: out of 100 priced US health stocks, 44 advanced and 50 declined. Notable movers include RXRX (Recursion Pharmaceuticals Inc) at USD 4.51 with a 2.59% decrease and a typical hold time of 22 days, HRTX (Heron Therapeutics Inc) at USD 0.34 rising 2.50% with a 35-day hold, and NUWE (Nuwellis Inc) at USD 0.68 down 2.41% with a 25-day hold. Pluang order activity shows RXRX heavily sold at 79%, while HRTX and NUWE have more balanced sell/buy splits.
XRP's price fell to around $1.45 following a $3.14 million net inflow into U.S. spot XRP ETFs on October 6, with Bitwise's inflows offsetting withdrawals from other funds. Despite the inflows, XRP dropped sharply during a crypto market selloff, losin...
Mantle (MNT) fell sharply by 11.4%, breaking its $0.6 support level and hitting a low of $0.54 before recovering slightly to $0.58. The decline was driven by intense selling pressure in the derivatives market, with open interest dropping 14% and deri...
Verizon and AT&T both offer attractive dividend yields, but Verizon stands out as the more reliable choice for long-term investors. Verizon's dividend yield is higher at 6.2%, supported by strong free cash flow growth, manageable debt levels, and a c...
Credo Technology, a company providing critical connectivity components for AI infrastructure, is experiencing rapid revenue growth of over 114% year-over-year, outperforming expectations with $479 million in quarterly revenue. Despite a recent stock ...
BD announced positive 9-month results from the AGILITY trial for its Revello™ Vascular Covered Stent treating iliac artery disease, showing 97.2% vessel patency and 98.3% freedom from reintervention. The study involved 120 patients across multiple co...
